AMPE:NYE-Ampio Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.88

Change

+0.09 (+5.03)%

Market Cap

USD 0.35B

Volume

2.45M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.49 (-0.59%)

USD150.10B 28.54 3.25
BHVN Biohaven Pharmaceutical Holdin..

+0.72 (+0.76%)

USD6.13B N/A N/A
MYOV Myovant Sciences Ltd

+0.32 (+1.54%)

USD1.90B N/A N/A
ADCT ADC Therapeutics SA

+0.25 (+1.09%)

USD1.80B -99,999.99 N/A
ZYME Zymeworks Inc

-1.93 (-5.06%)

USD1.76B 300.20 N/A
RCUS Arcus Biosciences, Inc

-0.71 (-2.99%)

USD1.70B N/A N/A
CVM CEL-SCI Corporation

+0.66 (+3.07%)

USD0.91B N/A N/A
RFL Rafael Holdings, Inc

-2.44 (-5.27%)

USD0.81B N/A N/A
ANVS Annovis Bio, Inc

+3.40 (+3.78%)

USD0.63B -99,999.99 N/A
LCTX Lineage Cell Therapeutics, Inc

-0.14 (-4.93%)

USD0.46B 3.63 N/A

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.24% 59% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.24% 56% F 71% C-
Trailing 12 Months  
Capital Gain 206.09% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 206.09% 92% A- 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 78.75% 88% B+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.75% 88% B+ 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 99.70% 19% F 6% F
Risk Adjusted Return 78.98% 85% B 84% B
Market Capitalization 0.35B 63% D 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 33% F 30% F
Price/Book Ratio 22.05 19% F 4% F
Price / Cash Flow Ratio -23.91 89% B+ 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -153.24% 33% F 9% F
Return on Invested Capital -132.20% 33% F 1% F
Return on Assets -55.74% 30% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 14.62 11% F 2% F
Short Percent 11.80% 19% F 26% F
Beta 1.83 38% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.